Despite treatment advancements, prognosis remains poor for many patients with advanced gastric/GEJ cancers¹

^*This includes patients with regional disease, or those whose cancer has spread to regional lymph nodes, and metastatic disease at the time of diagnosis. There are 30,300 estimated new cases in 2025.^3
†Assessed between 2015 and 2021 in the United States.^3
‡Defined as ≥ 75% of tumor cells with moderate (2+) to strong (3+) membranous staining.^9
§Defined as any percentage of tumor cells with moderate (2+) to strong (3+) membranous staining.^10
**Testing recommendations for GEJ cancers, HER2, and CLDN18.2 are in adenocarcinoma.^4,5

CLDN18.2, claudin-18 isoform 2; CPS, combined positive score; dMMR, deficient mismatch repair; FGFR2b, fibroblast growth factor receptor 2, isoform IIIb; FISH, fluorescence in situ hybridization; GEJ, gastroesophageal junction; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; MMR, mismatch repair; MSI-H, microsatellite instability-high; PD-L1, programmed cell death ligand 1.

References: 1. Sato Y, et al. J Clin Med. 2023;12:4646. 2. Bray F, et al. CA Cancer J Clin. 2024;74:229-263. 3. National Cancer Institute. https://seer.cancer.gov/statfacts/html/stomach.html. Accessed April 25, 2025. 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Gastric Cancer V.2.2025. ©National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed April 4, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Esophageal and Esophagogastric Junction Cancers V.3.2025. ©National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed April 22, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 6. Van Cutsem E, et al. Gastric Cancer. 2015;18:476-484. 7. Amonkar M, et al. J Clin Oncol. 2019;37:e15074. 8. Schoemig-Markiefka B, et al. Gastric Cancer. 2021;24:1115-1122. 9. Shitara K, et al. Lancet. 2023;401:1655-1668. 10. Rha SY, et al. JCO Precis Oncol. 2025;9:e2400710. 11. West NP, et al. Clin Oncol (R Coll Radiol). 2024;36:701-709.